(R)-methyl benzenesulfinate | 111698-33-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-methyl benzenesulfinate
• 英文别名: methyl (R)-benzenesulfinate
• CAS: 111698-33-0
• 化学式: C₇H₈O₂S
• 分子量: 156.205
• InChiKey: PSNSVDSRLUYDKF-SNVBAGLBSA-N

物化性质

• 沸点：
  260.3±23.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯亚磺酰氯 在 三氟化硼乙醚 、 三乙胺 作用下， 以 甲苯 为溶剂， 反应 4.75h， 生成 (R)-methyl benzenesulfinate
  参考文献：
  名称：

  [EN] 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE
  [FR] COMPOSÉS DE 2-AMINO-N- (ARYLSULFINYL)-ACÉTAMIDE EN TANT QU'INHIBITEURS DE L'AMINOACYL-ARNT SYNTHÉTASE BACTÉRIENNE

  摘要：

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些2-氨基-N-(芳基砜基)-乙酰胺类化合物，该化合物在诸多方面抑制（例如，选择性抑制）细菌氨酰-tRNA合成酶（aaRS）（例如，细菌亮氨酰-tRNA合成酶，LeuRS）。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制（例如，选择性抑制）细菌氨酰-tRNA合成酶；治疗通过抑制（例如，选择性抑制）细菌氨酰-tRNA合成酶而得到改善的疾病；治疗细菌感染等。

  公开号：

  WO2018065611A1

文献信息

• Acid Catalyzed Alcoholysis of Sulfinamides: Unusual Stereochemistry, Kinetics and a Question of Mechanism Involving Sulfurane Intermediates and Their Pseudorotation
  作者：Bogdan Bujnicki、Józef Drabowicz、Marian Mikołajczyk

  DOI：10.3390/molecules20022949

  日期：——

  formed in this reaction with a full or predominant inversion of configuration at chiral sulfur or with predominant retention of configuration. The steric course of the reaction depends mainly on the size of the dialkylamido group in the sulfinamides and of the alcohols used as nucleophilic reagents. It has been found that bulky reaction components preferentially form sulfinates with retention of configuration

  旋光性亚磺酸酯的合成已经通过旋光性亚磺酰胺的酸催化醇解完成。在该反应中形成亚磺酸盐，其中在手性硫处构型完全或主要反转，或构型主要保留。反应的空间过程主要取决于亚磺酰胺中的二烷基酰胺基的大小以及用作亲核试剂的醇的大小。已经发现，庞大的反应组分在保留构型的情况下优先形成亚磺酸盐。已经证明，通过向酸性反应介质中添加无机盐，可以将反应的立体化学结果从转化转变为保留，反之亦然。这种典型的双分子亲核取代反应的不同立体化学，
• Enantioselective sulfinylation of alcohols and amines by condensation with sulfinates
  作者：Minghong Liao、Yonggui Liu、Hongyan Long、Qin Xiong、Xiaokang Lv、Zhongfu Luo、Xingxing Wu、Yonggui Robin Chi

  DOI：10.1016/j.chempr.2024.02.016

  日期：2024.3

  Achieving the preparation of enantiomerically enriched -stereogenic compounds is a long-standing objective in stereoselective synthesis, owing to the fundamental importance and broad applications of these chiral scaffolds in various fields. Despite recent significant advancements, catalyst-controlled stereoselective synthesis of -stereogenic compounds remains to be a considerable challenge, particularly

  由于这些手性支架在各个领域的根本重要性和广泛应用，实现对映体富集的立体化合物的制备是立体选择性合成的长期目标。尽管最近取得了重大进展，但催化剂控制的立体选择性合成β-立体化合物仍然是一个相当大的挑战，特别是通过小分子催化剂。在此，我们公开了一种通过形成混合亚磺酸酐来活化亚磺酸盐来对醇和胺进行高度实用和对映选择性亚磺酰化的有机催化策略。一种简单的天然奎宁催化剂通过空间拥挤部分调节反应物种的结构，有效控制亲核 S-O 和 S-N 键结构的化学和对映选择性，提供各种具有优异光学性质的手性亚磺酰基衍生物纯度。值得注意的是，该协议很容易促进与各种天然产物和商业药物的偶联，这可以为重要的生物学有趣分子的后期多样化提供有吸引力的策略。
• Practical and highly stereoselective method for the preparation of several chiral arylsulfinamides and arylsulfinates based on the spontaneous crystallization of diastereomerically pure N-benzyl-N-(1-phenylethyl)-arylsulfinamides
  作者：Rui-Heng Zhu、Xiao-Xin Shi

  DOI：10.1016/j.tetasy.2011.01.028

  日期：2011.2

  A novel and simple process for the preparation of enantiomerically pure (S(s))-benzenesulfinamide (S(s))-3a, (S(s))-p-toluenesulfinamide (S(s))-3b, (S(s))-p-chloro-benzenesulfinamide (S(s))-3c and (S(s))-p-fluorobenzenesulfinamide (S(s))-3d has been developed. The treatment of arylsulfinyl chlorides with (R)-N-benzyl-1-phenylethanamine in the presence of excess triethylamine gave diastereomeric mixtures of N-benzyl-N-(1-phenylethyl)-arylsulfinamides 1, which underwent spontaneous crystallization to furnish diastereomerically pure (R,S(s))-N-benzyl-N-(1-phenylethyl)-arylsulfinamides (R,S(s))-1a-1d in 28%, 29%, 27% and 31% yields, respectively. The diastereomerically pure compounds (R,S(s))-1 were then converted into four enantiopure (R(s))-methyl arylsulfinates (R(s))-2, and finally into four enantiopure (S(s))-arylsulfinamides (S(s))-3 in good yields. (C) 2011 Elsevier Ltd. All rights reserved.
• 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE
  申请人：Oxford Drug Design Limited

  公开号：US20200039929A1

  公开（公告）日：2020-02-06

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(arylsulfinyl)-acetamide compounds that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-t RNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.
• [EN] 2-AMINO-N-(ARYLSULFINYL)-ACETAMIDE COMPOUNDS AS INHIBITORS OF BACTERIAL AMINOACYL-TRNA SYNTHETASE<br/>[FR] COMPOSÉS DE 2-AMINO-N- (ARYLSULFINYL)-ACÉTAMIDE EN TANT QU'INHIBITEURS DE L'AMINOACYL-ARNT SYNTHÉTASE BACTÉRIENNE
  申请人：OXFORD DRUG DESIGN LTD

  公开号：WO2018065611A1

  公开（公告）日：2018-04-12

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(arylsulfinyl)- acetamide compounds that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl- tRNA synthetase (aaRS) (e.g., bacterial leucyl-t RNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及某些2-氨基-N-(芳基砜基)-乙酰胺类化合物，该化合物在诸多方面抑制（例如，选择性抑制）细菌氨酰-tRNA合成酶（aaRS）（例如，细菌亮氨酰-tRNA合成酶，LeuRS）。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制（例如，选择性抑制）细菌氨酰-tRNA合成酶；治疗通过抑制（例如，选择性抑制）细菌氨酰-tRNA合成酶而得到改善的疾病；治疗细菌感染等。